Founder and chief executive officer of ImmunoTox, Inc., Kimber White, Ph.D. said, "We are looking forward to the opportunities that come with aligning ourselves with AIBioTech. Our capabilities complement AIBioTech's existing assay design and immunology services very well."
Dr. White will continue to serve as a consultant for AIBioTech. Other key employees of ImmunoTox have accepted positions and together with the acquisition of all necessary instrumentation, the ImmunoTox division will be able to continue its service offerings.
"We intend to leverage the expertise of ImmunoTox into expanded service offerings for our current customers including for the first time, flow cytometry," said AIBioTech president and chief scientific officer Robert B. Harris, Ph.D. "The ability to monitor the immune response of the host organism is a critical component along the path of drug (and chemical) development, and by adding these services to our research support repertoire, AIBioTech becomes even more competitive as the preferred full service contract research organization."